A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Condition studied

Hereditary Angioedema

Investigational medicinal product(s)

Eligibility

Primary endpoint

Incidence and severity of TEAEs.

Endpoint detail

The time-normalized number of Investigator-confirmed HAE attacks (per month), The time-normalized number of Investigator-confirmed HAE attacks requiring acute HAE therapy (per month), The -normalized number of moderate or severe Investigator confirmed HAE attacks (per month), The proportion of participants who have not experienced an Investigator-confirmed HAE attack (HAE attack-free)